Prandin (repaglinide), a new type 2 oral medication manufactured by Novo Nordisk, has been approved by the FDA.
The new drug stimulates the secretion of insulin from the pancreas. It was created with a quick onset and short duration of action to be especially effective at mealtimes.
Bill Poole, president of Novo Nordisk, claims that Prandin helps “people with type 2 manage their diabetes at mealtimes. Prandin is a highly potent, fast-working agent that is absorbed rapidly after dosing and clears quickly from the bloodstream.”
Prandin is expected to be available in the United States in the spring of this year.